PHASE I STUDY OF TOPOTECAN AND THORACIC RADIATION
OBJECTIVES:
I. Define the maximum tolerated dose and safety profile of topotecan (TOPO) administered
with daily high-dose thoracic radiotherapy to a total of 60 Gy in patients with solid tumor
or lymphoma.
II. Assess the qualitative and quantitative nature of the toxic effects encountered in this
treatment.
III. Estimate the tissue and tumor TOPO concentrations during radiotherapy by evaluating
plasma TOPO levels.
IV. Evaluate, using Western blot and immunohistochemical stain, the effects of
TOPO/radiotherapy on topoisomerase I levels in peripheral blood lymphocytes (PBL).
V. Determine whether TOPO induces apoptosis in PBL from this patient population.
VI. Examine tumor tissue pre- and post-treatment (if available) for topoisomerase I levels,
DNA damage, topoisomerase I/DNA complexes, and apoptotic events.
OUTLINE:
Radiosensitization plus Radiotherapy. Topotecan, TOPO, NSC-609699; plus external-beam
irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons
acceptable for the boost field).
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
George Wilding, MD
Study Chair
University of Wisconsin, Madison
United States: Food and Drug Administration
CDR0000063990
NCT00002625
March 1995
September 2000
Name | Location |
---|---|
University of Wisconsin Comprehensive Cancer Center | Madison, Wisconsin 53792 |